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Objective: This study presents the development and validation of MIS-A
(Medication Intake Survey-Asthma), a new self-report instrument measuring
key adherence properties during long-term asthma treatment.
Design: Within a longitudinal asthma cohort study in France and the United
Kingdom, adult patients and caregivers of children responded to computer-as-
sisted telephone interviews.
Main outcome measures: Scores for distinct adherence properties (taking
adherence, correct dosing, therapeutic coverage, drug holidays, overuse) and
composite measures were computed for several time intervals. We examined
distributions, longitudinal variation, associations between adherence scores
and concordance with adherence calculated from medication prescribing or
dispensing records.
Results: Nine hundred and two participants reported on adherence to 4481
medications on 4140 occasions. About 59.47 and 70.36% revealed < 100%
taking adherence in the last week and month; 42.76% had a drug holiday
of > 1 week in the last 4 months. Adherence varied within patients during the
follow-up (intra-class correlation = . 41–.71). Correlations between adherence
scores were moderate to strong (ρ = .51–.85, p ≤ .001), except medication
overuse (ρ = .04–.19, p ≤.05). Four-month taking adherence was associated
with dispensing adherence, but not with prescribing adherence (ρ = .33,
p < .001; and .12, p = .26).
Conclusion: MIS-A is a promising, easy-to-use self-report tool that can
capture accurately different adherence properties over a long time period.
Keywords: asthma; medication adherence; self-report; CATI
Background
Assessing medication adherence with reliable and valid tools is essential for research,
as well as for developing and implementing effective adherence support interventions
for chronic conditions (Nieuwlaat et al., 2014; Stirratt et al., 2015). Although numerous
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methods are available, the quest for optimal adherence assessment is still ongoing
(Lehmann et al., 2013). Electronic monitoring (EM) is valued for its high granularity (it
time-stamps each use of the monitoring device preceding medication intake), validity
(minimal systematic error due to its temporal proximity to medication intake) and relia-
bility (low random error if medication is taken from the device) (Lehmann et al., 2013;
Williams, Amico, Bova, & Womack, 2012). Raw EM data can be used ﬂexibly to
assess various adherence properties for different time windows (Blaschke, Osterberg,
Vrijens, & Urquhart, 2012; Vrijens & Goetghebeur, 1997). Yet, collection and analysis
of EM data are resource intensive and often raise practical difﬁculties (Bova et al.,
2005; Chan et al., 2013).
In contrast, self-reports of medication use are easier to collect and analyse, but tend
to suffer from substantial ceiling effects (Stirratt et al., 2015). Moreover, self-report
measures either collect high-resolution data over very short time periods (e.g. the last
2–3 days) and thus cannot detect long-term patterns (Chesney et al., 2000), or request
respondents to estimate their adherence over longer or non-speciﬁed time intervals
resulting in low granularity (Kerr et al., 2008; Mora et al., 2011; Morisky, Ang,
Krousel-Wood, & Ward, 2008). Several widely-used tools also suffer from concept con-
tamination (Gagné & Godin, 2005), as they measure a mix of behaviours and determi-
nants, which they combine in one overall score (Nguyen, Caze, & Cottrell, 2014). A
self-report adherence tool that captures patients’ actual adherence behaviour (i.e.
whether they take medication as prescribed) with optimal granularity, over a long time
interval, and with acceptable ceiling effects has yet to be developed.
This study aimed to apply state-of-the-art methodology (Gagné & Godin, 2005;
Stirratt et al., 2015; Williams et al., 2012) to develop a reliable and valid adherence
self-report tool that capitalises on the strengths of both EM (i.e. sufﬁciently detailed
data to estimate key adherence patterns over various time periods) and self-report (i.e.
easy to administer on a large scale), while attempting to address the main limitations of
currently available tools.
Methodological framework
Recall bias and social desirability are the main barriers to accurate reporting of
deviations from a prescribed medication regimen. Respondents ﬁnd it difﬁcult to access
information about (habitual) behaviours and events, particularly over/after longer time
intervals. They also tend to adjust their answers to meet the inquirer’s presumed expec-
tations, particularly if they perceive the question as having personally relevant conse-
quences. Thus, self-reported adherence often shows little variance and is usually higher
– with substantial ceiling effects – than when assessed through EM or medication
prescribing or dispensing records (Bender et al., 2000; Garber, Nau, Erickson, Aikens,
& Lawrence, 2004).
To improve recall, methodologists advise supporting respondents by identifying per-
sonal events that took place in the relevant time intervals (Belli, Smith, Andreski, &
Agrawal, 2007), using familiar and clear wording, specifying the time intervals of refer-
ence and requesting less detail over longer intervals (Gagné & Godin, 2005). Social
desirability is reduced by various techniques such as normalising behaviour, ensuring
conﬁdentiality or obtaining commitment for accurate reporting (Gagné & Godin, 2005).
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Moreover, interviewer-administered measures can facilitate the response process, for
example by correcting any biased perceptions on the consequences of reporting
non-adherence (Williams et al., 2012). Investigating via cognitive interviewing how
respondents understand questions and generate answers by accessing and selecting rele-
vant information has been proven useful in adherence measurement for improving ques-
tion comprehension and relevance in different respondent groups and contexts (Wilson
et al., 2013). Applying such methods in questionnaire design can improve psychometric
properties and reduce ceiling effects (Stirratt et al., 2015; Wilson, Carter, & Berg,
2009).
Self-reports have also been criticised for the limitations imposed by recall bias on
collecting high-granularity data on longer time intervals. EM records of individual med-
ication intake events allow for the examination of each event individually, and the com-
putation of various aggregate scores over various time windows, such as correct dosing,
taking adherence or timing adherence (Demonceau et al., 2013). However, maximum
granularity might not be necessary for all purposes and it might depend on which
adherence component (initiation, implementation or discontinuation; Vrijens et al.,
2012) is examined. Individual events are central when investigating medication (re-)ini-
tiation or discontinuation, or short-term effects of dose omission or mistiming (Blaschke
et al., 2012). Medication implementation is most commonly investigated via weekly or
monthly scores (Wilson et al., 2009), and fewer studies examine it as a series of indi-
vidual events or distinct adherence properties such as correct dosing or drug holidays
(e.g. De Geest et al., 2006). The relevance of these properties for clinical outcomes is
an empirical question; it may be condition- and medication-speciﬁc, and may depend
on the temporal dynamics of both adherence and health outcomes. Although current
self-reports do not do this, in principle self-reports can also collect data of sufﬁcient
granularity and accuracy by focusing directly on aggregate estimates of distinct
adherence properties. Such a tool would allow empirical investigation of the impact of
different adherence properties, as well as diagnosis and intervention in clinical practice
if certain adherence patterns prove relevant.
Self-report is often described as unreliable, yet this may be partly due to not using
appropriate methods for testing reliability (Voils, Hoyle, Thorpe, Maciejewski, & Yancy,
2011). Reliability represents the degree to which a measure is free of random measure-
ment error and is commonly tested via internal consistency and test–retest reliability.
The former assesses error due to item content and assumes all questions tap into the
same construct, while the latter estimates error due to context of measure administration
assuming temporal stability of the construct assessed (Viswanathan, 2005). Unsurpris-
ingly, measures that conceptualise adherence as a latent patient characteristic perform
well on these tests (Morisky et al., 2008; Reynolds et al., 2007; Thompson, Kulkarni,
& Sergejew, 2000), while measures that assess the quantity of medication taken over a
period of time compared to the quantity prescribed perform poorer (Jerant, DiMatteo,
Arnsten, Moore-Hill, & Franks, 2008). This is because, when conceptualised quantita-
tively in terms of patients’ dosing histories, adherence is a dynamic process and can
consist of different patterns at successive time points (Blaschke et al., 2012). Therefore,
self-report tools that are theoretically consistent with this conceptualisation require a
different approach to reliability testing, for example by examining associations
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between overlapping reports for the same time interval from different questions vs.
non-overlapping reports.
The low concordance of self-reported adherence with other adherence measures,
such as pharmacy dispensing records and EM, has cast doubt on the validity of
self-reports (Garber et al., 2004). Full concordance is, however, not expected as all
methods measure indirectly complementary aspects of medication use and show varying
degrees of subjectivity and construct-irrelevant variance (Berg & Arnsten, 2006;
Lehmann et al., 2013; Williams et al., 2012). For example, irrelevant actions for EM
are device use without taking medication, or using medication from another supply (e.g.
‘pocket-dosing’, Bova et al., 2005; de Bruin, 2013). Similarly, dispensing medication at
the pharmacy is not always followed by immediate use of that supply nor does it imme-
diately precede medication use, for example because patients still have medication
available from prior dispensations (Williams et al., 2012). Besides pharmacy records,
medication prescribing by patients’ doctors is sometimes used as a measure for medica-
tion adherence. Prescribing is even more distal from actual medication use than phar-
macy dispensing, and is not always followed by a corresponding pharmacy dispensing
event. Therefore, prescribing records would be expected to show lower concordance
with self-reports or EM than pharmacy dispensing data. Concordance between these
different measures can be increased by computing adherence scores for the same beha-
viour and time interval (Wilson et al., 2009), and may depend on context (e.g. type of
respondent; Bender et al., 2000) and tool characteristics (Garber et al., 2004). Thus,
validity tests for self-reported adherence need to consider these conceptual constraints,
and include an exploration of the possible inﬂuencing factors. Substantial variations in
concordance depending on factors such as respondent characteristics would indicate
bias; the opposite would support validity.
Study objectives
Asthma is a chronic airways disease which usually requires daily use of inhaled
corticosteroids (ICs) to control underlying inﬂammation and prevent exacerbations.
Empirical evidence shows that adherence to ICs is commonly low, which can have a
detrimental impact on asthma-related health outcomes (Engelkes, Janssens, de Jongste,
Sturkenboom, & Verhamme, 2015). Yet, the low quality and standardization of avail-
able measures hinders progress on understanding the role of adherence in asthma, and
improving adherence measurement is a methodological priority in this ﬁeld (Dima
et al., 2015). Therefore, within a prospective cohort study on asthma (ASTRO-LAB;
Van Ganse et al., 2015), we developed the Medication Intake Survey-Asthma (MIS-A),
a new tool for assessing self-reported medication adherence. MIS-A is delivered via
computer-assisted telephone interviews (CATIs), asks about different complementary
adherence properties (taking adherence, therapeutic coverage, correct dosing, drug holi-
days, overdosing), and applies strategies for reducing social desirability and improving
recall. We report its development and examine its psychometric properties by answering
the following research questions: (RQ1) Does MIS-A adequately capture
non-adherence? (RQ2) Are the different MIS-A scores non-redundant? (RQ3) Are
MIS-A scores reliable? and (RQ4) Are MIS-A scores valid?
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Methods
Study design and participants
The design of the ASTRO-LAB asthma cohort study is reported elsewhere (Van Ganse
et al., 2015). Brieﬂy, patients aged 6–40 years with ≥ 6 months of prescribed coverage
of daily controller inhalers (ICs and/or long-acting beta-agonists, LABA) in the past
12 months were selected from primary care or pharmacy records in France and the
United Kingdom (UK). After informed consent and enrolment procedures, participants
were followed up for maximum 24 months via monthly text messages, CATIs and
online surveys. CATIs were conducted every 4 months (regular CATIs) and when
patients reported recent asthma-related exacerbations (AEs) in their monthly text mes-
sage replies (AE CATIs). Recent occurrence of AEs was also probed during regular
CATIs. Adults and teenagers (≥12 years), and children (6–12 years) through caregivers,
reported on prescribed medication type and dosage, and on medication use before the
regular CATI and before an AE. Socio-demographics (gender, age, country, primary
care practice identiﬁer) were collected at enrolment from patient records. Electronic
medication dispensing claims were accessed for French participants (Moulis et al.,
2015) and medication prescribing data by primary care providers were accessed for
British participants (Blak, Thompson, Dattani, & Bourke, 2011). The resulting data-set
had a multilevel structure: participants could have multiple asthma medications that
were nested within CATI reports, there were multiple CATI reports nested within
patients and multiple patients were nested within primary care practices.
Development of the medication-related CATI questions
The CATI script was developed for adult English participants based on prior literature
on self-reported and EM adherence, and qualitative interviews with patients, caregivers
and health care professionals on asthma self-management in France (13 interviews) and
in the UK (26 interviews), and were revised iteratively within the project team.
It was translated to French by a specialised company using forward translation,
independent back translation, review with investigator input, and independent proofread-
ing. It was then adapted for caregivers reporting adherence for their children. The
resulting scripts were pretested with 5 adult patients and 4 caregivers via cognitive
interviews. Implementation in the online tool included extensive pretesting. Interviewers
were trained using a study manual, group sessions and feedback on their own perfor-
mance. They were also asked to provide feedback on their ﬁrst interviews to the investi-
gators. Improvements after pre-testing were implemented identically in the different
CATI versions.
The MIS-A script is available as a Supplementary Online Material 1 (SOM 1).
Essentially, MIS-A is a count-based recall measure (Williams et al., 2012) similar to the
AIDS Clinical Trials Group questionnaire (Reynolds et al., 2007); MIS-A develops fur-
ther the quantitative estimation of adherence on longer time periods consistent with
EM-based aggregate scores of medication implementation. We aimed for a minimum
number of complementary questions that would cover the type of adherence data that
one collects when using EM, adapted for recall capacities. Four months were selected
as the maximum recall period because of the current study design, but this could be
adapted to e.g. 2 or 3 months for other studies.
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Patients were ﬁrst asked the names of their currently prescribed medications. For
each medication pre-labelled as daily controller inhaler, detailed questions followed on
prescription start, daily dosage recommendations and adherence. The latter inquired
about: (Q1) number of inhalations used a day before; (Q2) number of days with no use
in the past 7 days; (Q3) number of days with perfect adherence in the past 7 days (i.e.
use according to prescribed dosage); (Q4) number of days with no use in the past
4 weeks; (Q5) number of weeks of treatment interruption in the past 4 months; and
(Q6) medication overuse in the past 4 months. If medications were
prescribed < 4 months before the CATI, only the questions regarding the more recent
period were asked (e.g. if prescribing happened two weeks before a CATI, only Q1 to
Q3 applied).
Question development and pretesting aimed to increase recall by asking more
detailed information for shorter time intervals and estimates of more memorable events
(such as drug holidays, and overuse) for longer time intervals, ordering the questions
chronologically, and collecting factual information (e.g. number of inhalations/days,
number of days without doses last week) rather than global adherence estimates (e.g.
percentages or perceived quality of implementation). It also aimed to facilitate natural
and parsimonious conversation, hence it included conditional questions where possible
(e.g. ask Q3 only if Q2 < 7 days), and used collected information to tailor subsequent
questions (e.g. the medication name). To further facilitate recall, interviewers were
instructed to introduce the MIS-A questions by clarifying the time interval targeted
(past 4 months) and identifying any public or personal events within this interval with
the respondent in free conversation (Belli et al., 2007). Moreover, interviewers were
trained to guide respondents to choose a distraction-free time interval and location for
the interview, use prompting to support the recall if respondents reported difﬁculties,
and reminders were included in the script for interviewers to use these techniques.
Proceeding to a next screen was conditioned by completion of current questions, and
interviewers were instructed to use ‘don’t know’ options only after providing adequate
recall support. To reduce social desirability, medication use questions were preceded by
an introduction normalising non-adherence, and several questions included normalising
words. Every CATI started with a refresher regarding response anonymity and indepen-
dence of interviewer from the patient’s health care provider. Interviewers were trained
to probe and address any concern about the study conduct before starting the CATI, and
to conduct interviews in a neutral, non-judgemental, supportive manner. Implementation
of these recommendations was monitored during data collection.
Data analysis
Data management and analysis were performed in R (R Core Team, 2013). We selected
from the ASTRO-LAB database CATI reports that referred to inhalers prescribed for
daily use at the time of the CATI, thus excluding treatments ended recently, prescribed
for as-needed use, or with recording errors. Data preparation included adjusting for any
inconsistencies between responses to MIS-A items, taking reports on shorter intervals
as reference (e.g. if a respondent reported no medication use a day before and 7 days of
adherent use in the last week, the latter was adjusted to 6 days). Single items were used
to compute scores for speciﬁc properties of medication implementation (see Table 1).
We used established deﬁnitions of taking adherence (percentage of prescribed doses
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taken), and correct dosing (percentage of treatment days when the patient took the
correct number of doses; Demonceau et al., 2013). To adapt to self-report on longer
time intervals, drug holidays were deﬁned as 7 or more consecutive days with no use
(as interruptions of one week or more were identiﬁed during pre-testing as more easy to
remember) and therapeutic coverage estimated the proportion of days with active
medication (as it was not possible to calculate intervals based on clinical data for each
medication as in Detry et al., 1994). Overuse was deﬁned as the proportion of medica-
tion taken over the prescribed quantity. Taking adherence was also computed over
1 week, 4 weeks and 4 months as composite scores considering the complementary
information provided by Q1-Q5 (algorithm presented in SOM 2).
Characteristics of patients and medications were summarised descriptively. To inves-
tigate whether MIS-A captures non-adherence (RQ1), we examined ceiling effects in
comparison to other asthma studies, and longitudinal variation in adherence scores.
Descriptive statistics were calculated for scores and compared to estimates from pub-
lished asthma studies using other self-report tools. To test whether MIS-A can detect
variation at within- and between-patient and between-practice levels, variation in the
four taking adherence scores was examined via three-level linear mixed-effects models
(LMM; reports nested within patients within practices; maximum likelihood estimation)
on a subsample of patients with long-term use of ICs-based medication. Thus, for this
analysis, we excluded patients with ≥ 1 reports with no daily medication (not pre-
scribed, ended recently or prescribed as needed), other asthma controllers (e.g. tiotro-
pium), ≥1 reports with no ICS-based controllers (only daily LABA prescribed) and
insufﬁcient follow-up (<2 reports). For reports with > 1 medication, average scores were
Table 1. Deﬁnition and operationalisation of MIS-A adherence scores.
No. Property Deﬁnition Operationalization
Q1 1-day taking
adherence
Proportion prescribed medication used a
day before
100 * quantity used a day
before/prescribed dose
Q2 1-week
therapeutic
coverage
Proportion days with medication use a week
before
100 * (7 – days with no
use)/7 days
Q3 1-week correct
dosing
Proportion days with adherent use a week
before
100 * days with adherent
use/7 days
Q4 1-month
therapeutic
coverage
Proportion days with medication use a
month before
100 * (28 - days with no
use)/28 days
Q5 4-month (no)
drug holidays
Proportion weeks with medication use
4 months before
100 * (16 – weeks
stopped)/16 weeks
Q6 4-month
overuse
Proportion overused medication 4 months
before, compared to prescribed quantity
100 * total quantity
overused/prescribed
quantity
CS1 1-week taking
adherence
Proportion prescribed medication used a
week before
Algorithm in SOM2
CS2 1-month taking
adherence
Proportion prescribed medication used a
month before
Algorithm in SOM2
CS3 4-month taking
adherence
Proportion prescribed medication used
4 months before
Algorithm in SOM2
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computed. Unconditional means models were performed to assess the proportion of
variance at different levels via intra-class correlation coefﬁcients (ICC); a cut-off of .05
was considered as indicating substantial variance to capture differences in adherence
(Heck, Thomas, & Tabata, 2013).
To investigate whether MIS-A scores are non-redundant (RQ2) we examined bivari-
ate correlations (Spearman’s ρ) at medication level, compared to a collinearity threshold
of .80 (Field, 2005). As the time intervals of some scores overlapped partially, correla-
tions were also performed after adjusting scores to refer to non-overlapping intervals
(e.g. adjusted Q2 referred to last week excluding a day before, which Q2 shared with
Q1). No tests of structural validity were performed, as the questions were not
hypothesised to reﬂect latent dimensions of adherence.
The reliability of MIS-A (RQ3) was examined by comparing correlations between
adjusted and non-adjusted scores. We expected that scores would be sensitive to adjust-
ment, i.e. adjusting scores to exclude temporal overlap between items would result in
lower correlations between adherence scores. This sensitivity to adjustment was taken to
reﬂect reliability of reports while accounting for temporal variation in behaviour, in
other words show that answers to different questions referring to the same time interval
are consistent, while reports on the same occasion but for non-overlapping time
intervals are less similar but still moderately to strongly associated.
To test the convergent and discriminant validity of MIS-A scores (RQ4), CATI data
were linked to French dispensing records via a probabilistic method or with UK pre-
scribing records via patient identiﬁcation numbers. We selected patient records with a
single type of medication matching between data sources and available data for a two-
year period around the patient’s ﬁrst CATI to obtain comparable scores. Medication dis-
pensing- and prescribing-based adherence estimates were computed for 4 months before
the ﬁrst CATI using a Continuous Medication Availability (CMA) algorithm. This algo-
rithm takes into account the timing of dispensing/prescribing events, the medication
supply available at the beginning of the time interval, and banking of new medication
until current supply is used as directed (described in Vollmer et al., 2012). We tested
the concordance between MIS-A 4-month taking adherence and dispensing/prescribing-
based adherence for the same interval via Spearman’s correlations, Wilcoxon rank sum
tests, concordance correlation coefﬁcients (CCC) and Bland-Altman plots, as recom-
mended for comparison of adherence scores (El Alili, Vrijens, Demonceau, Evers, &
Hiligsmann, 2016). Medium-sized correlations with dispensing-based estimates and
comparatively lower correlations with more distal prescription-based estimates were
considered to support convergent and discriminant validity, respectively. To explore pos-
sible inﬂuences on convergent validity (RQ4), we performed linear multiple regression
models with the absolute difference between MIS-A and dispensing-based adherence as
dependent variable, and type of report (patient or parent) and patient gender and age
as relevant predictor variables available in the CATI data-set. We considered weak/
non-signiﬁcant effects as indicating that convergent validity does not differ depending
on these characteristics.
For a third line of evidence on RQ1, the differences between MIS-A- and dispens-
ing/prescribing-based adherence were compared to previous studies. Smaller differences
would indicate a higher ability to detect non-adherence consistent with dispensing/
prescribing records. To examine RQ2 in more detail, the MIS-A scores were used to
predict dispensing-based four-month adherence in linear multiple regression models.
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Signiﬁcant effects of individual scores were interpreted as supporting non-redundancy,
i.e. different adherence properties might explain unique variance in related measures.
Results
From 1051 patients enrolled in the study in France and the UK, 4196 regular four-
monthly CATIs and 163 post-AE CATIs were conducted with 934 participants (1 to 10
CATIs per participant); 117 enrolled participants could not be reached for CATI. Adher-
ence reports on 3920 medications from 3634 regular CATIs, and 164 medications from
148 post-AE CATIs, met inclusion criteria. These reports were provided by 902 partici-
pants from 80 UK primary care practices and 243 French general practitioners. Of the
regular CATIs selected, 358 also included an AE report, followed by adherence reports
on 397 medications (ﬂow chart available in SOM 2). Thus, the total sample included
adherence reports on 4481 medications prior to 4140 occasions (AE or CATI). Partici-
pant and medication characteristics are presented in Table 2. A report could include
more medications: one medication was reported on 3813 occasions (92.10%), and a
maximum of 3 medications on 14 occasions.
Descriptive statistics of MIS-A scores
Descriptive statistics of MIS-A scores are presented in Table 3 (see SOM 2 for distribu-
tion plots). Taking adherence 1 day before the report (Q1) showed 34.06% of medica-
tions were underused, of which 19.39% were completely unused, and 3.73% was
overused. A week before (Q2 and Q3), 39.70% were unused for ≥ 1 day and 12.65%
were completely unused; 40.40% were used as prescribed the entire week. Therapeutic
coverage 1 month before (Q4) indicated that 55.02% were unused for ≥ 1 day (8.97%
completely unused). Four months before, drug holidays (Q5) were reported for 28.67%,
Table 2. Participant (n = 902) and medication (n = 4481) characteristics.
Unit Characteristic Value Statistic
Participant Country (%) France 732 (81.2)
UK 170 (18.8)
Gender (%) Female 426 (47.2)
Male 476 (52.8)
Age group (%) Adult/teenagers 683 (75.7)
Child 219 (24.3)
Mean age (sd) 21.86
(10.83)
Medication Type (%) FDC 2846 (63.5)
ICs 1282 (28.6)
LABA 353 (7.9)
Time interval covered
(%)
Only 1 day 13 (.3)
Up to 1 month 182 (4.1)
Up to 1 week 81 (1.8)
All 4 months 4205 (93.8)
Notes: OCs – oral corticosteroids; ICs – inhaled corticosteroids, LABA – long-acting beta2-agonists; FDC –
ﬁxed dose combination ICs and LABA.
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and overuse reports (Q6) showed that 18.93% were overused with > 1 inhalation.
Median taking adherence for 1 week, 1 month and 4 months (CS1, CS2 and CS3) was
85.71%. Ceiling effects (% of respondents with 100% adherence) were 24.5–61% for
Q1 to Q5, and 23.5–40.5% for the composite measures.
By comparison, self-reports of one-week adherence collected via a single survey
question in an asthma trial (Patel et al., 2013) resulted in 60–70% reports of 100%
adherence. In a daily diary study (Jentzsch, Camargos, Colosimo, & Bousquet, 2009),
self/parent reports resulted in a mean adherence of 97.9% in young people with asthma.
MIS-A scores have by comparison better distributions, hence it is more able to detect
non-adherence (RQ1).
Variation of MIS-A taking adherence scores at between-practice, between-patient and
within-patient levels
The subsample for linear mixed models included 3272 reports from 631 patients (in 67
UK primary care practices and 214 French general practitioners; ﬂow chart in SOM 2).
Table 4 summarises unconditional means models of the taking adherence scores. All 4
models indicate that a substantial proportion of variance was present between patients
(ICC = .24−.52) and between practices (UK primary care centres or French general
practitioners; ICC = .05−.10). For RQ1, this suggests that MIS-A taking adherence
scores can detect variation at these two levels. Moreover, the remaining within-patient
variance (ICC = .41−.71) indicates that patients had different adherence levels during
the follow-up. In other words, patients with high adherence in some CATIs were likely
to report suboptimal adherence at other times, and vice versa.
Bivariate associations and reliability of MIS-A scores
Spearman’s ρ correlations between MIS-A scores (including adjusted scores for non-over-
lapping time intervals) are presented in Table 5. Q1 to Q5 scores showed associations of
large effect size (ρ = .51−.85). Q6 (4-month overuse) was weakly associated with the
Table 3. Descriptive statistics MIS-A scores.
n Mean SD Median IQR Max
% adherent
(100%)
Q1: 1-day taking adherence 4395 77.89 55.97 100.00 50 1250 61.01
Q2: 1-week therapeutic
coverage
4348 77.26 35.42 100.00 28.57 100 58.51
Q3: 1-week correct dosing 4356 62.64 40.90 85.71 85.71 100 39.28
Q4: 1-month therapeutic
coverage
4257 77.83 32.67 92.86 28.57 100 42.74
Q5: 4-month (no) drug
holidays
3596 88.08 26.69 100.00 6.25 100 57.24
Q6: 4-month overuse 3623 1.74 8.76 .00 0 200 65.54
CS1: 1-week taking adherence 4284 70.29 35.69 85.71 50 100 40.53
CS2: 1-month taking
adherence
4149 70.69 33.60 85.71 50 100 29.64
CS3: 4-month taking
adherence
3462 71.18 31.82 85.71 50 100 23.54
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other items, except Q1 (ρ = .19). Only one-week and four-week therapeutic coverage (Q2
and Q4) showed correlations > .80, suggesting collinearity. All other associations were
below this threshold, indicating non-redundancy of individual items (RQ2). Composite
scores were associated with each other > .80, and were strongly associated with the ﬁrst 5
questions (ρ = .59−.97). All correlations were considerably reduced (ρ = .46−.73) when
scores were adjusted to exclude overlap in time intervals but remained moderate to strong
(see SOM 2 for scatterplots), suggesting reliability (RQ3).
Comparison of MIS-A scores with prescribing- or dispensing-based adherence (CMA)
Summary statistics, correlations, paired differences and concordance tests for therapeutic
coverage estimates are shown in Table 6 for patients with matching data regarding the
type of medication used (Bland-Altman plots in Figure 1). There was a moderate posi-
tive correlation with dispensing and a comparatively smaller non-signiﬁcant positive
correlation with prescribing CMA (ρ = .33 and .12 respectively). Hence MIS-A scores
showed convergent and discriminant validity (RQ4). The differences between MIS-A
vs. dispensing or prescribing CMA scores were 15 and 7%. In the above-mentioned
study by Jentzsch et al. (2009), dispensing estimates were 27.9% lower than self/parent
reports. We could not ﬁnd other published studies where both self-reported and dispens-
ing/prescribing adherence are expressed as percentages, to allow comparison. MIS-A
scores showed comparatively smaller differences, which supports its ability to detect
non-adherence consistent to alternative measures (RQ1).
Predicting differences between MIS-A- and dispensing-based adherence
The results of the linear multiple regression predicting differences between MIS-A and
dispensing-based adherence (in absolute values) are shown in Table 7. The type of
Table 4. Unconditional means models of MIS-A taking adherence scores from patients with
long-term use of ICs-based medication.
1-day 1-week 1-month 4-month
Intercept 81.345*** 73.946*** 74.062*** 73.756***
(1.305) (1.105) (1.063) (1.033)
Variance components
Level 1 residual 1515.05 539.93 451.72 404.11
Level 2 intercept 469.76 451.79 426.06 443.39
Level 3 intercept 78.80 56.90 52.16 32.07
Level 2 ICC .24 .46 .49 .52
Level 3 ICC .05 .10 .10 .07
Observations 3222 3149 3073 2619
Log Likelihood −16,685.43 −14,901.18 −14,302.64 −12,112.34
AIC 33,378.86 29,810.35 28,613.28 24,232.68
BIC 33,403.17 29,834.57 28,637.40 24,256.16
Notes: ICC = Intraclass Correlation Coefﬁcient; AIC = Akaike Information Criterion; BIC = Bayesian
Information Criterion.
***p ≤ .001.
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Table 6. Comparison of four-month MIS-A scores vs. dispensing/prescribing-based CMA scores
(summary statistics, correlations, paired differences and concordance).
Statistic French dispensing UK prescribing
N 302 87
CMA (mean (sd)) 60% (35%) 70% (32%)
MIS-A (mean (sd)) 75% (29%) 77% (27%)
Spearman’s ρ (p) .33 (p < .001) .12 (p = .261)
Wilcoxon (V, p) 8919, p < .001 1284, p = .202
CCC [95% CI] .30 [.21–.39] .19 [0–.38]
Note: CCC = concordance correlation coefﬁcient.
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Figure 1. Bland-Altman plots – 4-month MIS-A taking adherence vs. (a) dispensing- and
(b) prescribing-based adherence.
Table 7. Regression models of differences between four-month scores based on MIS-A vs. dis-
pensing records (n = 302).
Model
B SE B ß
Intercept 42.21 5.93
Report (parent) Count (%) 67(22.2) −3.33 5.09 −.05
Age (z-score) Mean (SD) 22(10.7) −9.77 4.25 −.18*
Gender (male) Count (%) 163(54.0) −2.46 3.17 −.05
adj R2 .013
F 2.272 (p = .08)
*p≤ .05.
Notes: B, unstandardised beta; SE, standard error; ß, standardised beta; adj R2, adjusted explained variance.
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interviewee and patient’s age and gender did not explain a signiﬁcant amount of
variance in concordance between self-report and dispensing-based adherence (F(3, 298)
= 2.27, p = .08; adjusted R2 = .01). Differences were signiﬁcantly lower for older
patients, yet the effect size was small. Thus, no substantial inﬂuences on convergent
validity were found among the available variables (RQ4).
Predicting dispensing-based adherence from MIS-A scores
Table 8 presents Spearman’s ρ correlations and linear multiple regression models pre-
dicting dispensing-based adherence (CMA scores) from MIS-A scores (excluding com-
posite scores and Q3 due to collinearity). All scores showed signiﬁcant correlations of
similar effect size with CMA scores. Higher one-day taking adherence (Q1) and four-
week therapeutic coverage (Q4) had unique contributions to predicting higher CMA in
both models; other scores did not contribute to explaining additional variance (F(5296)
= 12.21, p < .001 and F(2299) = 29.06, p < .001, adjusted R2 = .16 for both models).
These results suggest that Q1 and Q4 were complementary in relation to dispensing-
based adherence (RQ2), while others could be considered redundant in this respect.
Discussion
Self-report remains the most accessible and practical adherence measurement method.
Advances in theory and methodology of adherence measurement and psychometrics
were applied in this study to develop a next-generation adherence self-report that cap-
tures key properties of adherence usually only captured with EM, combines high granu-
larity of data over short time periods with estimations of adherence over longer periods,
and addresses recall and social desirability bias. MIS-A properties were evaluated in a
large, longitudinal sample of patients with persistent asthma in two countries. Our
results show that (1) MIS-A was able to detect non-adherence with low ceiling effects
Table 8. Spearman ρ correlations and regression models of dispensing-based four-month
adherence scores from MIS-A scores (n = 302).
Full model Final model
ρ B
SE
B ß B
SE
B ß
Intercept 19.50 8.21 21.87 5.41
Q1 .35*** .18 .07 .20** .20 .06 .21**
Q2§ .27***
Q3 .27*** −.01 .07 −.01
Q4 .32*** .25 .11 .22* .28 .08 .24***
Q5 .34*** .06 .14 .04
Q6 .21*** .34 .21 .09
adj R2 .16 .16
F 12.21 (p < .001) 29.06 (p < .001)
*p ≤ .05; **p ≤ .01; ***p ≤ .001.
§Q2 was not included in models due to collinearity with Q4 (ρ = .81).
Notes: ρ, bivariate Spearman correlation; B, unstandardised beta; SE, standard error; ß, standardised beta; adj
R2, adjusted explained variance.
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and substantial within-person variance; (2) it targeted related yet distinct adherence
properties; (3) reports were reliable; and (4) MIS-A four-month taking adherence
demonstrated convergent and discriminant validity. Hence, MIS-A is a promising, easy-
to-use self-report tool that can capture accurately different adherence properties over a
long time period.
MIS-A showed more variation in scores compared to other self-report measures in
asthma (RQ1). First, adherence levels and ceiling effects in our study were lower com-
pared to prior asthma studies using self-report measures (Jentzsch et al., 2009; Patel
et al., 2013). The higher levels of non-adherence identiﬁed also indicate that MIS-A has
higher validity, as self-reports are characterised by high speciﬁcity (Stirratt et al., 2015).
Second, multilevel unconditional means models showed that MIS-A was able to capture
variation in adherence within-patient, between-patients and between-practices. These
results are consistent with studies showing long-term variation in ICs use in asthma
based on electronic health care data (e.g. Laforest et al., 2016). Third, four-month tak-
ing adherence estimates were more similar to dispensing and prescribing-based esti-
mates, than the only other similar comparison we could ﬁnd (Jentzsch et al., 2009).
These results suggest that respondents were able to remember and were comfortable
with reporting suboptimal adherence when it occurred.
The associations between the MIS-A scores indicate that they largely offer
complementary information on a variable behaviour (RQ2). Among these scores, one-
day taking adherence and therapeutic coverage (one- or four-week) were predictive of
four-month dispensing-based adherence. Overuse was less common and not associated
with underuse reports, suggesting that patients when underusing medication do not nec-
essarily also overuse inhalers in the same four-month time period. Composite taking
adherence scores were strongly associated with underuse scores, as they were computed
based on this information; they would need to be used separately in further analyses
depending on the study aims.
We propose that adherence is better conceptualised as a dynamic behaviour in line
with recent consensus on deﬁning adherence to medications as a process (Vrijens et al.,
2012). Thus, common reliability and validity tests (e.g. factor analysis, Cronbach’s α)
are not applicable. Such tests have been reported for other measures (e.g. Mora et al.,
2011; Reynolds et al., 2007), and assume that questions are equivalent indicators of a
stable latent dimension. Recent variance decomposition methods that estimate reliability
in longitudinal data using generalizability theory (Cranford et al., 2006) also assume the
existence of a latent construct. This does not apply to count-based measures such as
MIS-A, as scores refer to different time intervals in a variable behaviour. Hence, we
adopted another approach to reliability testing, which was based on sensitivity-to-adjust-
ment: inter-item correlations were lower, but still moderate to strong, after the overlap
in time interval between items was excluded. These analyses suggest that the MIS-A is
a reliable self-reported adherence tool.
Concordance with four-month dispensing-based adherence was moderate, in line
with other reports in the literature (Garber et al., 2004). For example, medium positive
associations (ρ = .21−.26) were found between dispensing-based adherence and three
other self-report measures in a heterogeneous sample of long-term medication users
(Cook, Wade, Martin, & Perri, 2005), as well as between claims and self-reported ICS
adherence (r = .35) in adults with asthma (Erickson, Coombs, Kirking, & Azimi, 2001).
The comparatively higher association with dispensing than with prescribing supports
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convergent vs. discriminant validity, as prescribing is more distal than dispensing rela-
tive to people actually using the medication. Prescribing-based adherence may neverthe-
less be relevant clinically and related to dispensing (Mabotuwana, Warren, Harrison, &
Kenealy, 2009; Taylor, Chen, & Smith, 2014). Differences between MIS-A and dispens-
ing estimates were not higher when parents reported for their children compared with
adult self-reports, and not inﬂuenced by participant’s gender and age, suggesting that
validity is not inﬂuenced by these characteristics. Other contextual inﬂuences (for
example parents’ perceived social desirability or involvement in their child’s medication
administration) might play a role and would need to be explored further.
The present study and tool show some limitations. First, MIS-A focuses on medica-
tion implementation, as it was intended to assess patients with ongoing long-term
medication; hence, exact dates of treatment initiation and discontinuation, the other two
components of the recent consensus-based medication adherence taxonomy (Vrijens
et al., 2012), are not precisely captured. The practical applications of this taxonomy are
under development, and most adherence measures target implementation (Nguyen et al.,
2014). In MIS-A, 0% four-month taking adherence could be coded as either non-initia-
tion or non-persistence; future versions could include preliminary questions on time of
initiation and whether and when discontinuation occurred. Second, the MIS-A items
were chosen in the context of asthma and ASTRO-LAB, and other adherence properties
possibly relevant for other long-term conditions were excluded, e.g. timing adherence
for assessing the exact times of medication ingestion (Demonceau et al., 2013).
Adaptations to other conditions would need to consider the potential relevance of other
adherence properties. Third, the MIS-A validity testing was limited by the data avail-
able. Hence, although our study provides strong support for its validity, MIS-A would
beneﬁt from further validation in studies that collect EM data, or dispensing and pre-
scribing data from the same sample. Fourth, the impact of adherence on health out-
comes is currently under investigation in ASTRO-LAB and would also test MIS-A’s
criterion-related validity (Berg & Arnsten, 2006). Should this impact prove signiﬁcant,
MIS-A would represent a valuable tool also in clinical consultations for investigating
individual causes of worsening asthma.
These ﬁrst validation results suggest that MIS-A is an easy, inexpensive, reliable
and valid self-report method for assessing speciﬁc adherence properties over long time
periods. MIS-A is ready to use for measuring adherence to asthma controllers via CATI,
and can be adapted as a self-administered questionnaire, or for other types of medica-
tions or chronic conditions. It can also be employed as adherence diagnosis tool in gen-
eral practice or community pharmacies either as routine monitoring on selected patients
(e.g. with severe asthma) or retrospectively after an AE to identify preceding events.
Should MIS-A prove valid in such contexts, interventions could be developed to target
speciﬁcally the adherence properties linked with worsening health status.
More broadly, the development of MIS-A illustrates how self-report, when carefully
designed and used, is able to produce rich and valid information on implementation pat-
terns of long-term treatment. Further improvements in adherence self-report need to be
explored and tested for different administration contexts, respondent characteristics and
in different chronic conditions.
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